|
Current issue
Archive
Videos
Articles in press
About the journal
Supplements
Editorial board
Reviewers
Abstracting and indexing
Subscription
Contact
Instructions for authors
Publication charge
Ethical standards and procedures
Editorial System
Submit your Manuscript
|
1/2013
vol. 115 abstract:
Case report
Treatment of cystoid macular edema with bevacizumab in course of Irvine-Gass syndrome
Bartosz Izdebski
1
,
Zofia Michalewska
1, 2
,
Krzysztof Dzięgielewski
2
,
Jerzy Nawrocki
1, 2
,
Dominik Odrobina
1, 2
Klinika Oczna 2013, 115 (1): 61-64
Online publish date: 2013/03/28
View
full text
Get citation
ENW EndNote
BIB JabRef, Mendeley
RIS Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
Purpose: To determine clinical effect of intravitreal bevacizumab (Avastin) in patients with cystoid macular edema after cataract surgery.
Material and methods: Four eyes of four patients treated with 1 intravitreal injection of 1.25 mg Avastin. In three cases duration of cystoid macular edema was less then 4 months, in one eye cystoid macular edema was chronic (more than 4 months). Visual acuity and clinical effect in spectral optical coherence tomography (central retinal thickness and fovea anatomy) was examined before and after intravitreal injection. Results: Visual acuity improved in 3 of 4 patients. In acute cystoid macular edema final visual acuity was 0.8–0.9, in chronic cystoid macular edema patient visual acuity improved from 0.05 to 0.2. In 3 of 4 patients central retinal thickness decreased and fovea anatomy was normalized. In patient with no clinical and anatomical improvement spectral optical coherence tomography examination revealed epiretinal membrane. Conclusions: Intravitreal Avastin may be successful treatment in most Irvine-Gass syndrome cases. The condition that exclude patients from bevacizumab treatment is horizontal (epiretinal membrane), and vertical traction revealed in spectral optical coherence tomography. keywords:
pseudophakic cystoid macular edema, Irvine-Gass syndrome, bevacizumab, spectral optical coherent tomography, epiretinal membrane |
|
POLSKI
